



KAREN L. SMITH, MD, MPH
Director and State Public Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



EDMUND G. BROWN JR.
Governor

OFFICE OF AIDS (OA)
AIDS Drug Assistance Program (ADAP)

Management Memorandum
Memorandum Number: 2017-12

Date: December 21, 2017

TO: ADAP ENROLLMENT WORKERS

SUBJECT: **ADDITION OF A NEW ANTIRETROVIRAL (ARV) MEDICATION TO THE AIDS DRUG ASSISTANCE PROGRAM (ADAP) FORMULARY**

Effective December 21, 2017, dolutegravir/rilpivirine (Juluca) has been added to the ADAP formulary. Juluca is a fixed-dose tablet containing two previously approved ARV drugs, dolutegravir (Tivicay) and rilpivirine (Edurant), to treat adults with HIV-1 infections whose virus has been suppressed on a consistent treatment regimen for at least six months and who have no history of treatment failure and no known mutations associated with resistance to dolutegravir or rilpivirine. Juluca received approval from the federal Food and Drug Administration (FDA) on November 21, 2017 as a once-daily, single-tablet complete treatment regimen for HIV-1 infected patients. The two drugs that make up Juluca are already on the ADAP formulary as stand-alone medications and as ingredients of other combination drugs. The ADAP Medical Advisory Committee voted to recommend Juluca for addition to the formulary on November 29, 2017.



If you have any questions regarding the addition of this new ARV to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

A handwritten signature in blue ink, appearing to read "Sandra Robinson", with a long horizontal flourish extending to the right.

Sandra Robinson, MBA
Chief, ADAP Branch
Office of AIDS